Research & Development
Zealand Pharma completes enrolment in Phase 3 SBS trial
20 January 2022 -

Danish biotechnology company Zealand Pharma A/S (NASDAQ:ZEAL) (CPH:ZEAL) has completed patient enrolment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the company announced on Thursday.

Glepaglutide, Zealand Pharma's long-acting GLP-2 analog, is a potential new treatment for short bowel syndrome (SBS). It is being investigated for once or twice weekly administration with an autoinjector and has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA).

Full results of the trial are expected in the third quarter of 2022.

With completion of patient enrolment into EASE-SBS 1, the EASE-SBS 2 extension trial has been amended to allow for direct enrolment without prior participation in EASE-SBS 1. The EASE-SBS 2 trial is a two-year Phase 3b trial assessing safety and efficacy of glepaglutide dosed once and twice weekly.

Login
Username:

Password: